Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 200

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

Open access
Dixon, W. G., Watson, K. D., Lunt, M., Mercer, L. K., British Society For Rheumatology Biologics Register Control Centre Consortium, Hyrich, K. L., Symmons, D. P. M., British Society for Rheumatology Biologics Register · 2010 · Arthritis Care & Research

Abstract

Objective: To explore the influence of anti–tumor necrosis factor (anti‐TNF) therapy upon the incidence of cancer in patients with rheumatoid arthritis (RA) and prior malignancy. Methods: Using data from the British Society for Rheumatology Biologics Register, a national prospective observational study established in 2001, we identified 293 patients with a prior malignancy from over 14,000 patients with RA. We compared rates of incident malignancy in 177 anti‐TNF–treated patients and 117 patients with active RA treated with traditional disease‐modifying antirheumatic drugs (DMARDs), all with prior malignancy. One patient switched therapy and contributed to both cohorts. Results: The rates of incident malignancy were 25.3 events/1,000 person‐years in the anti‐TNF cohort and 38.3/1,000 person‐years in the DMARD cohort, generating an age‐ and sex‐adjusted incidence rate ratio of 0.58 (95% confidence interval 0.23–1.43) for the anti‐TNF–treated cohort compared with the DMARD cohort. Of the patients with prior melanomas, 3 (18%) of 17 in the anti‐TNF cohort developed an incident malignancy, compared with 0 of 10 in the DMARD cohort. Conclusion: The way in which UK rheumatologists are selecting patients with RA and prior malignancy to receive anti‐TNF therapy is not leading to an increased risk of incident malignancy. Although reassuring, these results should not be interpreted as indicating that it is safe to treat all RA patients with prior malignancy with anti‐TNF therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acr.20129

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 200

Metadata

Authors
Dixon, W. G., Watson, K. D., Lunt, M., Mercer, L. K., British Society For Rheumatology Biologics Register Control Centre Consortium, Hyrich, K. L., Symmons, D. P. M., & British Society for Rheumatology Biologics Register
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2010-05-28
Volume
62
Issue
6
Pages
755-763
ISSN
  • 0893-7524 (ISSN-L)
  • 2151-464X
  • 2151-4658
OpenAlex
W2055176162
Cited by
200
References
1
FWCI
13.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register. https://app.cochat.ai/papers/10.1002/acr.20129
The paper
Dixon, W. G., Watson, K. D., Lunt, M., Mercer, L. K., British Society For Rheumatology Biologics Register Control Centre Consortium, Hyrich, K. L., Symmons, D. P. M., & British Society for Rheumatology Biologics Register. (2010). Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register. Arthritis Care & Research. https://doi.org/10.1002/acr.20129

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.